New HIV vaccine with a 97% antibody response rate shows promise in ‘landmark’ first-in-human trial.
IAVI and Scripps Research reported that the vaccine which is being developed to act as an immune primer, to trigger the activation of naïve B cells via a process called germline-targeting, as the first stage in a multi-step vaccine regimen to elicit the production of many different types of broadly neutralizing antibodies (bnAbs), successfully stimulated the production of the rare immune cells needed to generate antibodies against HIV in 97 percent of participants.
European Pharmaceutical Review reported that stimulating the production of bnAbs has been pursued as a holy grail in HIV for decades. It is hoped that these specialized blood proteins could attach to HIV surface proteins called spikes, which allow the virus to enter human cells, and disable them via difficult-to-access regions that do not vary much from strain to strain.
Dr. William Schief, a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI’s Neutralizing Antibody Center, whose laboratory developed the vaccine said;
“We and others postulated many years ago that to induce bnAbs, you must start the process by triggering the right B cells – cells that have special properties giving them potential to develop into bnAb-secreting cells.
“In this trial, the targeted cells were only about one in a million of all naïve B cells. To get the right antibody response, we first need to prime the right B cells. The data from this trial affirms the ability of the vaccine immunogen to do this.
“This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens as well. With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens.”
One of the lead investigators on the trial, Dr. Julie McElrath, senior vice president and director of Fred Hutch’s Vaccine and Infectious Disease Division said the trial was “a landmark study in the HIV vaccine field,” adding that they had demonstrated “success in the first step of a pathway to induce broadly neutralizing antibodies against HIV-1.”
In the Phase I IAVI G001trial, 48 healthy adult volunteers were enrolled to receive either a placebo or two doses of the vaccine compound, EOD-GT8 60mer, along with an adjuvant developed by the GlaxoSmithKline.
The company’s said this study sets the stage for additional clinical trials that will seek to refine and extend the approach, with the long-term goal of creating a safe and effective HIV vaccine. As a next step, the collaborators are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. According to the team, using mRNA technology could significantly accelerate the pace of HIV vaccine development, as it did with vaccines for COVID-19.
Dr. Dennis Burton, professor and chair of the Department of Immunology and Microbiology at Scripps Research, scientific director of the IAVI Neutralizing Antibody Center and director of the NIH Consortium for HIV/AIDS Vaccine Development added;
“This is a tremendous achievement for vaccine science as a whole.
“This clinical trial has shown that we can drive immune responses in predictable ways to make new and better vaccines, and not just for HIV. We believe this type of vaccine engineering can be applied more broadly, bringing about a new day in vaccinology.”
It is also believed that the same approach could be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C and malaria. Here